Research Article

**Serum Paraoxonase 1 Activity Is Associated with Fatty Acid Composition of High Density Lipoprotein**

Maryam Boshtam, Amirnader Emami Razavi, Morteza Pourfarzam, Mohsen Ani, Gholam Ali Naderi, Gholam Basati, Marjan Mansourian, Narges Jafari Dinani, Seddigheh Asgary, and Soheila Abdi

1 Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Iran National Tumor Bank, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Clinical Biochemistry, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran
5 Epidemiology and Biostatistics Department, Health School, Isfahan University of Medical Sciences, Isfahan, Iran
6 Apply Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
7 Department of Physics, Safadasht Branch, Islamic Azad University, Tehran, Iran

Correspondence should be addressed to Amirnader Emami Razavi; razavinader@gmail.com

Received 17 June 2013; Revised 12 August 2013; Accepted 25 August 2013

Academic Editor: Natacha Turck

Copyright © 2013 Maryam Boshtam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Introduction.** Cardioprotective effect of high density lipoprotein (HDL) is, in part, dependent on its related enzyme, paraoxonase 1 (PON1). Fatty acid composition of HDL could affect its size and structure. On the other hand, PON1 activity is directly related to the structure of HDL. This study was designed to investigate the association between serum PON1 activity and fatty acid composition of HDL in healthy men.

**Methods.** One hundred and forty healthy men participated in this research. HDL was separated by sequential ultracentrifugation, and its fatty acid composition was analyzed by gas chromatography. PON1 activity was measured spectrophotometrically using paraxon as substrate.

**Results.** Serum PON1 activity was directly correlated with the amount of stearic acid and dihomo-gamma-linolenic acid (DGLA). PON1/HDL-C was directly correlated with the amount of miristic acid, stearic acid, and DGLA and was inversely correlated with total amount of \( \omega-6 \) fatty acids of HDL.

**Conclusion.** The fatty acid composition of HDL could affect the activity of its associated enzyme, PON1. As dietary fats are the major determinants of serum lipids and lipoprotein composition, consuming some special dietary fatty acids may improve the activity of PON1 and thereby have beneficial effects on health.

1. **Introduction**

Serum paraoxonase 1 (PON1) is a 45 kDa glycoprotein which can catalyze the hydrolysis of various organophosphates and nerve agents [1, 2] and also metabolize some drugs and prodrugs by its lactonase activity [3]. This enzyme which is located on high density lipoprotein (HDL) particles protects low density lipoprotein (LDL) phospholipids against oxidation [4]. Decreased PON1 activity has been addressed in several diseases such as coronary artery diseases (CAD) [5], type I diabetes [6], obesity [7], and renal failure [8].

It is evident that PON1 activity is influenced by a variety of agents like environmental, pharmacological, and lifestyle factors as well as age and sex [2, 5, 9–11]. Dietary fats have been suggested as an important relevant factor [12, 13]. Studies have presented that dietary fatty acids may
affect PON1 activity [14]. Polyenoic fatty acids have shown considerable inhibitory effect on PON1 activity [15], while monoenoic acids (especially oleic acid) protect PON1 from oxidative inactivation [16]. It has been also indicated that replacement of dietary saturated fats with trans fats in healthy men and women leads to a small reduction in the serum PON1 activity [17].

Serum PON1 is almost exclusively found in association with HDL particles. The lipid composition of HDL can influence its size [18] and structure and is determined by a combination of various factors including dietary intake, metabolism, and storage [19]. So, dietary fats may affect PON1 activity via changing the phospholipid composition of HDL. On the other hand, it seems that any variation in HDL fatty acid composition could alter the function of HDL and the activity of its related enzyme, PON1.

The association between serum PON1 activity and the lipid content of HDL has not yet been investigated. Therefore, in this study we investigated the association between serum PON1 activity and fatty acid composition of HDL in healthy male subjects.

2. Subjects and Methods

2.1. Subjects. 140 healthy men aged between 20 and 50 with a mean value of 32.5 ± 8.2 years were selected from a representative sample of the Iran center population. All participants were nonsmoker and nonobese (mean body mass index (BMI) 23.6 ± 3.3 kg/m²) volunteers, without diabetes (fasting blood sugar (FBS) ≤ 110 mg/dL), cardiovascular disease, familiar hypercholesterolemia, and dyslipidemia or any other recognized lipid-related disorders. A questionnaire containing demographic characteristics, medical history, and lifestyle information was completed for each subject by interview. All participants signed an informed consent document approved by the Isfahan University of Medical Sciences Ethics Committee.

2.2. Biochemical Analysis. A 12–14 h fasting blood sample (20 mL) was taken from each subject by venipuncture. Serum samples were separated by centrifugation at 3000 RPM for 15 min, and then 100 μL aliquots of each sample were stored at −80°C until the measurement of the serum PON1 activity. Serum HDL cholesterol (HDL-C) was determined at the day of sampling using enzymatic methods.

2.3. Serum PON1 Activity. Serum PON1 activity was assayed using 2 mM paraoxon (diethyl p-nitro-phenyl phosphate, Sigma Chemical Co., St. Louis, Mo, USA) as the substrate in 100 mM tris buffer (pH 8.0) containing 2 mM of CaCl₂ [20]. A 40 μL aliquot of serum was added to 500 μL of substrate medium, and the initial rate of hydrolysis (generation of p-nitrophenol) was monitored at 412 nm, using a continuously recording spectrophotometer (UV 3100, Shimadzu, Kyoto, Japan) over a period of 2 min. A PON1 activity of 1 Unit/L was defined as 1 μmole of p-nitrophenol formed per minute. The molar extinction coefficient of p-nitrophenol was taken at 17,000 M/cm [21]. All assays were performed in duplicate at 25°C. The coefficient of variation (CV%) for 10 measurements was 2.9%.

2.4. HDL Separation. Serum HDL was separated (1.063 g/cm³ < ρ < 1.21 g/cm³) by a three-stage method [18]. Briefly, 5.9 mL of serum added to 3 mL of solution A (containing 0.195 mmol NaCl, 0.62 mmol NaOH, 0.01% (w/v) EDTA-Na₂, d = 1.006 g/mL) in polystyrene ultracentrifuge tube (Optisal, Beckman/Coulter, Fullerton, California, USA) in a discontinuous density gradient fashion, and centrifuged at 60000 rpm for 12 h at 16°C, with the acceleration of “5” and deceleration of “7.” The very low density lipoprotein (VLDL) fraction accompanied with 3 mL of the upper layer solution was removed, and then 3 mL of solution B (containing 24.8 g NaBr in 100 mL of solution A) was added to the residual content of tubes for the second stage and centrifuged at 60000 rpm for 12 h at 16°C, acceleration: “9” and deceleration: “7.” Then the LDL fraction accompanied by 3 mL of the supernatant was removed. In the last stage the residual content of tubes was mixed with 3 mL of solution C (containing 78.32 g of NaBr in 100 mL of solution A) and centrifuged for another 12 h at 16°C, acceleration: “9” and deceleration: “7.” After centrifugation, the HDL fraction appearing as a yellow band at the supernatant was separated and stored at −80°C for further analysis. The centrifugations were done in a Beckman Coulter Optima L-100 XP ultracentrifuge equipped with a 90Ti fixed angle rotor. Protein concentration of the collected HDL fraction was measured using the Lowry method [22].

2.5. Fatty Acids Measurement of HDL

2.5.1. Calibration Standards and Chemical Compounds. A commercially available standard mixture of 37 fatty acid methyl ester (FAME) and a series of individual standards of fatty acid methyl esters including myristic acid (C14:0), palmitic acid (C16:0), stearic acid (C18:0), arachidonic acid (C20:4n6), and myristoleic acid (C14:1) were used for calibration. Boron trifluoro methanol (BF₃·M) and butylated hydroxy toluene (BHT) were obtained from Sigma Chemical Co., St. Louis, Mo, USA) were used for calibration. Boron trifluoro methanol (BF₃·M) and butylated hydroxy toluene (BHT) were obtained from Sigma Chemical Co. (St. Louis, Mo, USA), and all other reagents, chemical compounds, and solvents were obtained from Merck (Merck Co., Darmstadt, Germany).

2.5.2. Lipid Extraction. Lipids of HDL fraction were extracted according to the Folch method [23]. 100 μL of HDL samples were added to a 3 mL of chloroform-methanol (2:1 v/v) in a test tube. 100 μL BHT (5 mg/mL in chloroform) as antioxidant and 100 μL heptadecanoic acid (1000 μg/mL in chloroform) as internal standard (to monitor the recovery rate) were added to the mixture, and the tubes were vortexed.
vigorously for 1 min. 600 µL of 0.9% NaCl solution was mixed again prior to a brief centrifugation (100 RPM, 3 min) to separate the phases. The chloroform phase containing lipids (lower layer) was separated by a pasteur pipette and transferred to another test tube. Anhydrous sodium sulfate was added to remove any remnant water, and the lipid extract was transferred to a 15 mL Teflon liner screw cap tube and dried under nitrogen gas at room temperature before methylation [18].

2.5.3. Fatty Acid Methyl Ester Preparation. The fatty acid methyl esters were prepared according to the method of Morison and Smith, using BF3 [24]. 1 mL hexane and 1 mL BF3/methanol (13%) were added to the dried lipid extract in 15 mL Teflon liner screw cap tube and mixed well. The mixture was heated at 100°C in an oven for 45 min. After cooling, 0.5 mL hexane and 0.5 mL HPLC grade water were added to the mixture, shackled and centrifuged. Then, the methyl esters fraction in the upper hexane layer was separated by a Pasteur pipette and dried under nitrogen gas. Fatty acid methyl esters were dissolved in 200 µL hexane prior to GC analysis.

2.5.4. Instrumentation, Chromatography and Detection Method. Fatty acid composition of HDL was measured by a gas chromatography method. GC analyses were done by a Younglin GC-FID system model, Acme 6000 M (Young Lin Co., Hogye, Anyang, Korea), equipped with an FID detector. The injector and detector temperature was held at 260°C, and the flame was maintained with 40 mL/min H2 and 300 mL/min air. Helium was used as the detector auxiliary gas at a flow of 28 mL/min. Chromatography was carried out using an SP-2560 fused silica capillary column 100 m × 0.25 mm × 0.2 µm film thickness (Supelco Co., Bellefonte, PA). Helium was used as the carrier gas at a flow rate of 18 cm/s with constant flow compensation. Sample injections of 1 µL were performed with a split ratio of 17:1 for the analysis. The oven temperature was programmed from 140 to 245°C at a rate of 4°C/min after an initial time hold of 5 min and the final time hold of 15 min (the total analysis time was 45.00 min).

2.6. Statistical Analyses. Statistical analyses were performed using SPSS version 16.0 (SPSS, IL, USA). Quantitative parameters were compared between groups by one way ANOVA using Tukey correction for post hoc multiple comparisons except for nonnormal distributed variables that were analyzed by a nonparametric Kruskal-Wallis test. Correlations between variables with normal distribution were calculated by Pearson correlation coefficient analysis. Spearman's rho correlation coefficient analysis was used to calculate the correlation between variables that were not normally distributed (i.e., serum PON1 activity, PON1/HDL-C ratio, PON1/Apo A-I ratio, palmitoleic acid, linolenic acid, arachidic acid, ETA, EPA, DHA, EPA: DHA, and ω3 index). All data were expressed as mean ± standard error or median and interquartile range. A P value < 0.05 was considered statistically significant.

3. Results

Subjects were divided into three experimental groups in accordance with their serum HDL-C levels to analyze the association between serum PON1 activity and HDL fatty acid composition (group 1: HDL ≤ 39 mg/dL; 49 subjects, group 2: 39 mg/dL < HDL ≤ 49 mg/dL; 46 subjects and group 3: 49 mg/dL < HDL; 45 subjects). All subjects in the three groups were age matched, and mean values for HDL-C were 32.3 ± 4.1, 43.5 ± 2.9, and 61.9 ± 7.2 mg/dL in groups 1, 2, and 3, respectively.

Table 1 shows the fatty acid composition of HDL as percent of total fatty acids in three experimental groups. The major fatty acid of HDL in all groups was palmitic acid and the minor one was ETE. The proportion of saturated fatty acids (SFA) in group 1 of experiment was significantly higher compared to that in group 2 (P < 0.001) and group 3 (P = 0.005). Among the SFAs, palmitic acid and stearic acid were significantly higher in group 1 when compared to that in groups 2 and 3 (P < 0.01). There was no significant difference in monounsaturated fatty acids (MUFA) of HDL particles among three groups. Polyunsaturated fatty acids (PUFA) were significantly lower in group 1 in comparison with group 2 (P < 0.01) and group 3 (P < 0.05). Among the PUFAs, ETE was significantly higher in group 1 compared to that in groups 2 and 3 (P < 0.05). Inversely, AA was significantly lower in group 1 compared to that in group 2 (P < 0.05) and group 3 (P < 0.001). The proportion of ω3 fatty acids to total fatty acids was significantly higher (P < 0.05), and the proportion of ω6 fatty acids to total fatty acids was significantly lower (P < 0.01) in group 3 of the study in comparison with the other groups. A significant trend was seen for higher SFA to unsaturated fatty acids (UFA), SFA:MUFA, and SFA:PUFA ratios in group 1 of the study. The ratio of AA: EPA was significantly higher in group 3 compared to that in group 1 (P < 0.01) and group 2 (P < 0.05).

Associations of serum PON1 activity, PON1/HDL-C ratio, and PON1/apo A-I ratio with HDL fatty acid composition in all participants are indicated in Table 2. Serum PON1 activity was directly correlated with stearic acid (r = 0.190, P < 0.05) and DGLA (r = 0.260, P < 0.01). Serum PON1 activity adjusted for serum apo A-I level (PON1/HDL-C ratio) was directly correlated with mirtic acid (r = 0.190, P < 0.05), stearic acid (r = 0.237, P < 0.01), and DGLA (r = 0.257, P < 0.01). There was a negative correlation between the PON1/HDL-C ratio and total ω6 fatty acids of HDL particles (r = −0.198, P < 0.05). Serum PON1 activity adjusted for serum apo A-I level (PON1/apo A-I ratio) was directly correlated with stearic acid (r = 0.179, P < 0.05) and DGLA (r = 0.278, P < 0.01) but not with mirtic acid. It also was directly correlated with palmitoleic acid (r = 0.197, P < 0.05). A negative correlation was seen between PON1/apoA-I ratio with total ω6 fatty acids of HDL particles (r = −0.184, P < 0.05).

The correlations between PON1 activity and fatty acids of HDL in each individual group of the study are shown in Table 3. As indicated in group 1 of the study with the serum HDL-C levels lower than 40 mg/dL, serum PON1 activity strongly correlated with MUFAs (r = 0.487, P < 0.01)
Table 1: Comparison of HDL fatty acid composition between groups.

| Fatty acids | Group 1 HDL ≤ 39 | Group 2 39 < HDL ≤ 49 | Group 3 49 < HDL | P value (G1 & G2) | P value (G1 & G3) | P value (G2 & G3) |
|------------|------------------|------------------------|------------------|-------------------|-------------------|-------------------|
| SFA        | 42.52 ± 0.42     | 40.48 ± 0.24           | 40.97 ± 0.23     | 0.000             | 0.005             | 0.581             |
| C14:0 (myristic acid) | 0.49 ± 0.02    | 0.43 ± 0.02            | 0.40 ± 0.01      | 0.088             | 0.002             | 0.416             |
| C16:0 (palmitic acid) | 25.94 ± 0.26    | 25.21 ± 0.26           | 25.37 ± 0.30     | 0.154             | 0.300             | 0.924             |
| C18:0 (stearic acid) | 15.78 ± 0.23    | 14.53 ± 0.17           | 14.90 ± 0.16     | 0.000             | 0.004             | 0.354             |
| C20:0 (arachidic acid) | 0.32 ± 0.01    | 0.31 ± 0.02            | 0.30 ± 0.02      | 0.921             | 0.895             | 0.998             |
| UFA        | 57.48 ± 2.8      | 59.52 ± 1.6            | 59.03 ± 2.2      | 0.000             | 0.005             | 0.581             |
| MUFA       | 10.34 ± 0.19     | 10.58 ± 0.20           | 10.37 ± 0.22     | 0.689             | 0.995             | 0.749             |
| C14:1 (myristoleic acid) | 0.23 ± 0.01    | 0.21 ± 0.01            | 0.21 ± 0.01      | 0.185             | 0.209             | 0.997             |
| C16:1 (palmitoleic acid) | 0.65 ± 0.03    | 0.73 ± 0.05            | 0.64 ± 0.04      | 0.357             | 0.994             | 0.307             |
| C18:1n9c (oleic acid) | 9.6 ± 0.16      | 9.64 ± 0.17            | 9.51 ± 0.18      | 0.748             | 0.975             | 0.867             |
| PUFA       | 47.14 ± 0.48     | 48.93 ± 0.29           | 48.66 ± 0.47     | 0.009             | 0.031             | 0.889             |
| C18:3n3 (ALA) | 1.21 ± 0.08     | 1.43 ± 0.09            | 1.29 ± 0.07      | 0.136             | 0.775             | 0.431             |
| C20:3n3 (ETE) | 0.16 ± 0.02     | 0.14 ± 0.02            | 0.11 ± 0.01      | 0.050             | 0.036             | 0.313             |
| C20:5n3 (EPA) | 0.68 ± 0.04     | 0.99 ± 0.17            | 0.59 ± 0.04      | 0.070             | 0.811             | 0.015             |
| C22:6n3 (DHA) | 6.61 ± 0.33     | 6.96 ± 0.33            | 6.15 ± 0.20      | 0.664             | 0.513             | 0.129             |
| C18:2n6c (LA) | 23.85 ± 0.43    | 23.80 ± 0.44           | 24.23 ± 0.54     | 0.997             | 0.834             | 0.800             |
| C20:3n6 (DGLA) | 3.83 ± 0.13     | 3.79 ± 0.19            | 3.66 ± 0.17      | 0.984             | 0.727             | 0.830             |
| C20:4n6 (AA) | 11.60 ± 0.31    | 12.82 ± 0.25           | 13.53 ± 0.39     | 0.026             | 0.000             | 0.217             |

ALa: α-linolenic acid, ETA: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomogamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids. Data are expressed as mean ± SE and indicated the percent of fatty acid to total fatty acids.

especially palmitoleic acid (r = 0.457, P < 0.01) and oleic acid (r = 0.474, P < 0.01). In this group, PON1 activity positively correlated with EPA (r = 0.352, P < 0.05) and DGLA (r = 0.402, P < 0.01) and negatively correlated with LA (r = −0.332, P < 0.05). The ratio of SFA:MUFA was inversely (r = −0.414, P < 0.01) and the ratio of EPA:DHA was directly (r = 0.339, P < 0.05) correlated with serum PON1 activity in the first group of the study. In the second group with serum HDL-C levels between 40 and 50 mg/dL, correlations between PON1 activity and fatty acids of HDL were completely different. PON1 activity negatively correlated with myristic acid (r = −0.296, P < 0.05), arachidic acid (r = −0.315, P < 0.05), myristoleic acid (r = −0.342, P < 0.05), ALA (r = −0.301, P < 0.01), ETE (r = −0.297, P < 0.01), EPA (r = −0.295, P < 0.05), and the ratio of EPA:DHA (r = −0.310, P < 0.05) and positively correlated with AA (r = 0.425, P < 0.01). There were no significant associations between PON1 activity and HDL fatty acids in the third group of participants with the serum HDL-C levels higher than 50 mg/dL.

4. Discussion

The associations between fatty acid composition of HDL and the activity of its related enzyme, PON1, in healthy male subjects with different ranges of serum HDL-C levels were investigated in this study. Results indicated that serum PON1 activity was directly correlated with stearic acid and DGLA levels. Serum PON1 activity adjusted for serum HDL-C level (PON1/HDL-C ratio) also was directly correlated with miristic acid, stearic acid, and DGLA levels.

It is evident that PON1 activity is influenced by a variety of agents including environmental, pharmacological and lifestyle factors as well as age and sex [2, 5, 9–11]. Dietary fats have been proposed as an important relevance factor [12–14].
Table 2: Bivariate correlations between serum PON1 activity, PON1/HDL-C ratio, and PON1/apo A-I ratio with fatty acid composition of HDL particles in all participants.

| Fatty acids (percent of total FA) | Serum PON1 activity | P value | PON1/HDL-C ratio | P value | PON1/apo A-I ratio | P value |
|----------------------------------|---------------------|---------|------------------|---------|-------------------|---------|
| SFA                              | 0.097               | NS      | 0.136            | NS      | 0.109             | NS      |
| C14:0 (myristic acid)            | 0.070               | NS      | 0.190            | 0.028   | 0.123             | NS      |
| C16:0 (palmitic acid)            | 0.029               | NS      | 0.039            | NS      | 0.037             | NS      |
| C18:0 (stearic acid)             | 0.190               | 0.027   | 0.237            | 0.006   | 0.179             | 0.038   |
| C20:0 (arachidic acid)           | −0.064              | NS      | 0.026            | NS      | −0.004            | NS      |
| MUFA                             | −0.097              | NS      | −0.136           | NS      | −0.109            | NS      |
| C14:1 (myristoleic acid)         | 0.112               | NS      | 0.111            | NS      | 0.178             | 0.039   |
| C16:1 (palmitoleic acid)         | −0.024              | NS      | 0.034            | NS      | 0.044             | NS      |
| C18:1 (oleic acid)               | 0.141               | NS      | 0.157            | NS      | 0.197             | 0.022   |
| PUFA                             | 0.102               | NS      | 0.095            | NS      | 0.164             | NS      |
| C18:3n3 (ALA)                    | 0.057               | NS      | −0.115           | NS      | −0.107            | NS      |
| C20:3n3 (ETE)                    | −0.108              | NS      | −0.070           | NS      | −0.069            | NS      |
| C20:5n3 (EPA)                    | −0.052              | NS      | 0.047            | NS      | −0.059            | NS      |
| C22:6n3 (DHA)                    | −0.037              | NS      | 0.007            | NS      | −0.020            | NS      |
| C18:2n6c (LA)                    | −0.100              | NS      | −0.106           | NS      | −0.133            | NS      |
| C20:3n6 (DGLA)                   | 0.260               | 0.002   | 0.257            | 0.003   | 0.278             | 0.001   |
| C20:4n6 (AA)                     | 0.038               | NS      | −0.075           | NS      | −0.010            | NS      |

| SFA : UFA ratio                  | 0.097               | NS      | 0.136            | NS      | 0.109             | NS      |
| SFA : MUFA ratio                 | −0.074              | NS      | −0.054           | NS      | −0.134            | NS      |
| SFA : PUFA ratio                 | 0.077               | NS      | 0.133            | NS      | 0.111             | NS      |
| Total α3 fatty acids             | −0.047              | NS      | 0.022            | NS      | −0.010            | NS      |
| Total α6 fatty acids             | −0.111              | NS      | −0.198           | 0.022   | −0.184            | 0.033   |
| ω6 : α3 ratio                    | −0.005              | NS      | −0.088           | NS      | −0.062            | NS      |
| AA : EPA ratio                   | −0.036              | NS      | −0.148           | NS      | −0.107            | NS      |
| EPA : DHA ratio                  | 0.054               | NS      | 0.067            | NS      | 0.084             | NS      |

ALA: α-linolenic acid, ETE: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, NS: not significant.

Studies have exhibited that dietary fatty acids may influence PON1 activity [15]. Polyenoic fatty acids have demonstrated a considerable inhibitory effect on PON1 activity [16], while monoenoic acids (especially oleic acid) protect PON1 against oxidative damages [25]. Furthermore, replacement of dietary saturated fats with trans fats in healthy men and women moderately decreases the activity of PON1 [26].

HDL is a phospholipid and protein containing particle to which PON1 is also attached. The lipid composition of HDL which can influence its structure is determined by a combination of various factors including dietary intake, metabolism, and storage [19]. So, dietary fats may affect PON1 activity via changing the phospholipid composition of HDL. On the other hand, it seems that any variation in HDL fatty acid composition may affect its three-dimensional structure and physical characteristics including size and zeta potential of HDL particles and consequently alter the function of HDL and the activity of its related enzyme, PON1.

In this research we investigated the individual correlations between PON1 activity and fatty acid composition of HDL in each group of the study, separately (Table 3). The association between PON1 activity and HDL fatty acid composition was completely different in each group of the study. In subjects with serum HDL-C levels of 39–49 mg/dL (group 2 of the study) SFAs had negative correlations with serum PON1 activity. This correlation was not found in other groups. MUFAs (especially palmitoleic acid and oleic acid) were positively correlated with serum PON1 activity in subjects with serum HDL-C levels lower than 40 mg/dL (group 1 of the study), while in group 2 this correlation was different and myristoleic acid was inversely associated with PON1 activity. Among PUFAs in group 1, EPA and DGLA were positively and LA was negatively correlated with serum PON1 activity. In group 2 this correlation was different again in that ALA, ETE, and EPA were negatively and AA was positively correlated with serum PON1 activity. These findings are in
Table 3: Bivariate correlations between serum PON1 activity and fatty acid composition of HDL particles between groups.

| Fatty acids (percent of total FA) | Group 1 (HDL ≤ 39) | Serum PON1 activity | Group 2 (39 < HDL ≤ 49) | Group 3 (49 < HDL) |
|----------------------------------|--------------------|---------------------|------------------------|--------------------|
| SFA                              | 0.021              | −0.147              | 0.038                  |                    |
| C14:0 (myristic acid)            | 0.155              | −0.296*             | −0.074                 |                    |
| C16:0 (palmitic acid)            | −0.044             | −0.192              | 0.078                  |                    |
| C18:0 (stearic acid)             | −0.060             | 0.133               | 0.078                  |                    |
| C20:0 (arachidic acid)           | 0.006              | −0.315*             | −0.106                 |                    |
| UFA                              | −0.021             | 0.147               | 0.038                  |                    |
| MUFA                             | 0.487**            | −0.104              | −0.168                 | −0.099             |
| C14:1 (myristoleic acid)         | 0.106              | −0.342*             | −0.168                 | −0.099             |
| C16:1 (palmitoleic acid)         | 0.457**            | −0.058              | −0.203                 |                    |
| C18:1 (oleic acid)               | 0.474**            | −0.189              | −0.099                 |                    |
| PUFA                             | 0.222              | 0.425**             | 0.136                  | 0.040              |
| C18:3n3 (ALA)                    | −0.235             | −0.301*             | −0.112                 |                    |
| C20:3n3 (ETE)                    | −0.141             | −0.297*             | 0.130                  |                    |
| C20:5n3 (EPA)                    | 0.352*             | −0.295*             | −0.106                 |                    |
| C22:6n3 (DHA)                    | −0.260             | 0.191               | −0.077                 |                    |
| C18:2n6c (LA)                    | −0.332*            | −0.145              | 0.201                  |                    |
| C20:3n6 (DGLA)                   | 0.402**            | 0.144               | 0.136                  |                    |
| C20:4n6 (AA)                     | 0.222              | 0.425**             | 0.250                  |                    |
| SFA : UFA ratio                  | −0.006             | −0.144              | 0.040                  |                    |
| SFA : MUFA ratio                 | −0.414**           | 0.082               | 0.165                  |                    |
| SFA : PUFA ratio                 | 0.091              | −0.215              | 0.008                  |                    |
| Total α3 fatty acids             | −0.231             | 0.002               | −0.086                 |                    |
| Total ω6 fatty acids             | −0.037             | 0.177               | 0.074                  |                    |
| ω6 : ω3 ratio                    | 0.190              | −0.054              | 0.127                  |                    |
| AA : EPA ratio                   | −0.227             | 0.205               | 0.047                  |                    |
| EPA : DHA ratio                  | 0.339              | −0.310*             | −0.007                 |                    |

ALA: α-linolenic acid, ETE: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids.

*Significant at the level of 0.05.
**Significant at the level of 0.01.

accordance with those of Nguyen and Sok investigation [16]. There was no correlation between serum PON1 activity and fatty acid composition of HDL in subjects with serum HDL-C levels higher than 49 mg/dL (the third group of our study).

To the best of our knowledge there is no investigation evaluating the relationship between HDL fatty acid composition and PON1 activity. The association between serum PON1 activity and dietary factors has been reported in some studies. For example, Tomas and coworkers suggested that high intake of oleic acid from olive oil has a positive effect on serum PON1 activity in men especially in subjects with the PON1-192 RR polymorphism [27]. Findings of another study demonstrated that meals rich in olive oil can increase postprandial serum PON1 activity in diabetic women [28]. In an in vitro study, beneficial protecting and stabilizing effect of oleic acid on PON1 against oxidative inactivation was observed [25].

We found a negative correlation between the PON1/HDL-C ratio and total ω6 fatty acids of HDL particles in all subjects, but no correlation was found between serum PON1 activity and total ω3 fatty acids or the ratio of ω6 : ω3 in all subjects. Calabresi et al. have reported that a ω-3 polyunsaturated fatty acid concentrate can enhance plasma PON1 concentration and HDL<sub>2</sub> subfraction in familial combined hyperlipidemia patients [12]. Also, in another study the inhibitory effect of polyenoic fatty acids, especially linoleic acid, on PON1 activity was observed [9]. In addition, opposite to the triolein-rich diet that caused a significant increase in PON1 activity, fish oil showed significant decrease in an animal study [14]. One point that deserved further attention was the relatively strong association between MUFAs (myristoleic acid, palmitoleic acid, and oleic acid) and PON1 activity only in group 1 (HDL-C < 39). The reason of the relations is not clear, but it may be a protective compensation mechanism by which the fatty acids play in the subjects with low levels of HDL-C.

Contrary to the presented studies, some researchers have not found any relationship between PON1 activity and daily intake of total lipids and SFAs [11]. It is suggested that dietary fats may change the serum PON1 activity via affecting the synthesis and secretion of phospholipids and apo-A-I within very high density lipoprotein (VHDL), the main transporter of PON1 and LCAT molecules in blood [14].

Although there is a relative agreement between the results obtained in the present study with the others, some controversy is observed even between other researches, which can
be due to many factors beside the genetic variations. HDL lipid composition's determinants including dietary intake, metabolism, storage, and exchange among compartments are one of them [19]. In the mentioned studies only the effect of dietary fatty acids has been defined; however, there is a strong interaction between all the determinants of HDL lipid composition.

5. Conclusion

The protective role of HDL against oxidative stress-related disease seems to be a complicated and multifactorial procedure that depends on the HDL particle size, number, composition, distribution, and its related enzyme PON1. The major determinants of HDL fatty acid composition are serum and dietary fats. Fatty acid composition of HDL is the major factor which can influence the metabolism of HDL and its particle characterization such as size and zeta potential and can change the PON1 activity. So, the enhancing effect of fatty acids like DGLA on PON1 activity in this research may be the result of the changes in HDL size distribution toward the smaller particle size. However, more investigations are needed to evaluate the exact relationship between the type of HDL fatty acids with PON1 activity in different subclasses of HDL. These pieces of information may help to design therapeutic protocols toward beneficial modifications of HDL characteristics and its related enzyme, PON1.

Conflict of Interests

The authors of the study declare that they have no conflict of interests.

Acknowledgments

This research was funded by Grant no. 188140 from Isfahan University of Medical Sciences and Isfahan Cardiovascular Research Institute. The authors would like to thank Professor Nizal Sarrafzadegan and Dr. Ahmad Bahonar director and manager of the center, and also Dr. Hashem Nayeri and other their colleagues in the laboratory of Cardiovascular Research Institute for supporting them.

References

[1] D. I. Draganov and B. N. La Du, “Pharmacogenetics of paraoxonases: a brief review,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 369, no. 1, pp. 78–88, 2004.
[2] A. Tward, Y. R. Xia, X. P. Wang et al., “Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice,” Circulation, vol. 106, no. 4, pp. 484–490, 2002.
[3] L. G. Costa, T. B. Cole, G. P. Jarvik, and C. E. Furlong, “Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism,” Annual Review of Medicine, vol. 54, pp. 371–392, 2003.
[4] P. J. Barter, S. Nicholls, K. Rye, G. M. Anantharamiah, M. Navab, and A. M. Fogelman, “Antiinflammatory properties of HDL,” Circulation Research, vol. 95, no. 8, pp. 764–772, 2004.
[5] O. Fridman, A. G. Fuchs, R. Porcile, A. V. Morales, and L. O. Gariglio, "Paraoxonase: its multiple functions and pharmacological regulation," Archives de Cardiologie de Mexico, vol. 81, no. 3, pp. 251–260, 2011.
[6] J. Valabhji, A. J. McColl, M. Schachter, S. Dhanjiil, W. Richmond, and R. S. Elkeles, "High-density lipoprotein composition and paraoxonase activity in type 1 diabetes," Clinical Science, vol. 101, no. 6, pp. 659–670, 2001.
[7] G. Ferretti, T. Bacchetti, S. Masiangelo, and V. Bicchigia, "HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects," Obesity, vol. 18, no. 6, pp. 1079–1084, 2010.
[8] S. A. Saeed, M. Elsharkawy, K. Elsaeed, and O. Fooda, "Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients," Hemodialysis International, vol. 12, no. 4, pp. 471–479, 2008.
[9] L. G. Costa, A. Vitalone, T. B. Cole, and C. E. Furlong, "Modulation of paraoxonase (PON1) activity," Biochemical Pharmacology, vol. 69, no. 4, pp. 541–550, 2005.
[10] W. H. F. Sutherland, R. J. Walker, S. A. de Long, A. M. van Rij, V. Phillips, and H. L. Walker, "Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1340–1347, 1999.
[11] N. Ferré, J. Camps, J. Fernández-Ballart et al., “Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population,” Clinical Chemistry, vol. 49, no. 9, pp. 1491–1497, 2003.
[12] L. Calabresi, B. Villa, M. Canavesi et al., “An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia,” Metabolism, vol. 53, no. 2, pp. 153–158, 2004.
[13] G. Ferretti and T. Bacchetti, “Effect of dietary lipids on paraoxonase-1 activity and gene expression,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 2, pp. 88–94, 2012.
[14] B. J. Kuchchodkar, A. G. Lacko, L. Dory, and T. V. Fungwe, “Dietary fat modulates serum paraoxonase 1 activity in rats,” Journal of Nutrition, vol. 130, no. 10, pp. 2427–2433, 2000.
[15] S. D. Nguyen, N. D. Hung, P. Cheon-Ho, K. M. Ree, and S. Dai-Eun, "Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1)," Biochimica et Biophysica Acta, vol. 1790, no. 3, pp. 155–160, 2009.
[16] S. D. Nguyen and D. E. Sok, "Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization," Biochemical Journal, vol. 375, no. 2, pp. 275–285, 2003.
[17] N. M. de Roos, E. G. Schouten, L. M. Scheek, A. van Tol, and R. S. Elkeles, "Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women," Metabolism, vol. 51, no. 12, pp. 1534–1537, 2002.
[18] A. E. Razavi, M. Pourfarzam, M. Ani, and G. A. Naderi, “The associations between high-density lipoprotein mean particle size and its fatty acid composition,” Biomarkers in Medicine, vol. 7, no. 2, pp. 235–245, 2013.
[19] P. Risié, S. Eligini, S. Ghezzi, S. Colli, and C. Galli, “Fatty acid composition of plasma, blood cells and whole blood: relevance for the assessment of the fatty acid status in humans,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 76, no. 6, pp. 363–369, 2007.
[20] A. E. Razavi, M. Ani, M. Pourfarzam, and G. A. Naderi, “Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity,” *Journal of Research in Medical Sciences*, vol. 17, no. 11, pp. 1020–1026, 2012.

[21] J. Bełtowski, G. Wójcicka, and A. Jamroz, “Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia,” *Atherosclerosis*, vol. 170, no. 1, pp. 21–29, 2003.

[22] M. A. K. Markwell, S. M. Haas, L. L. Bieber, and N. E. Tolbert, “A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples,” *Analytical Biochemistry*, vol. 87, no. 1, pp. 206–210, 1978.

[23] J. Folch, M. Lees, and G. H. S. Stanley, “A simple method for the isolation and purification of total lipides from animal tissues,” *The Journal of Biological Chemistry*, vol. 226, no. 1, pp. 497–509, 1957.

[24] W. R. Morrison and L. M. Smith, “Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride—methanols,” *Journal of Lipid Research*, vol. 5, pp. 600–608, 1964.

[25] S. D. Nguyen and D. E. Sok, “Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization,” *Biochemical Journal*, vol. 375, no. 2, pp. 275–285, 2003.

[26] N. M. de Roos, E. G. Schouten, L. M. Scheek, A. van Tol, and M. B. Katan, “Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women,” *Metabolism*, vol. 51, no. 12, pp. 1534–1537, 2002.

[27] M. Tomás, M. Sentí, R. Elosua et al., “Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity,” *European Journal of Pharmacology*, vol. 432, no. 2-3, pp. 121–128, 2001.

[28] A. J. Wallace, W. H. F. Sutherland, J. I. Mann, and S. M. Williams, “The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes,” *European Journal of Clinical Nutrition*, vol. 55, no. 11, pp. 951–958, 2001.